Synthesis and biological characterisation of 18F-SIG343 and 18F-SIG353, novel and high selectivity σ2 radiotracers, for tumour imaging properties

EJNMMI Research

Volumn 3, Issue 1, 2013, Pages 1-16

  Nguyen, Vu H ^a   Pham, Tien ^a   Fookes, Chris ^a   Berghofer, Paula ^a   Greguric, Ivan ^a   Arthur, Andrew ^a   Mattner, Filomena ^a,b   Rahardjo, Gita ^a   Davis, Emma ^a   Howell, Nicholas ^a   Gregoire, Marie Claude ^a   Katsifis, Andrew ^a,b   Shepherd, Rachael ^a  

^a AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

A375 cell line; PET imaging; Phthalimide; Sigma receptors

Indexed keywords

2 [4 [6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL]BUTYL] 5 FLUOROISOINDOLINE 1,3 DIONE F 18; 2 [5 [6,7 DIMETHOXY 3,4 DIHYDROISOQUINOLIN 2(1H) YL]PENTYL] 5 FLUOROISOINDOLINE 1,3 DIONE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SYNTHESIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMAGING; METABOLITE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOACTIVITY; RADIOCHEMISTRY; RADIORECEPTOR ASSAY; RAT; TUMOR IMAGING;

EID: 84891380015     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-3-80     Document Type: Article

References (60)

1. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE: The effects of morphine-and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 1976, 197:517-532.
2. Walker JM, Bowen WD, Walker FO, Matsumoto RR, de Costa B, Rice KC: Sigma receptors: biology and function. Pharmacol Rev 1990, 42:355-402.
3. Quirion R, Bowen WD, Itzhak Y, Junien JL, Musacchio JM, Rothman RB, Su TP, Tam SW, Taylor DP: A proposal for the classification of sigma binding sites. Trends Pharmacol Sci 1992, 13:85-86.
4. Hellewell SB, Bowen WD: A sigma-like binding site in rat pheochromocytoma (PC12) cells: decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain. Brain Res 1990, 527:244-253.
5. McLean S, Weber E: Autoradiographic visualization of haloperidol-sensitive sigma receptors in guinea-pig brain. Neuroscience 1988, 25:259-269.
6. Walker JM, Bowen WB, Roberts AH, de Costa BR, Rice KC: Autoradiographic distribution of [3H]-(+)-pentazocine binding sites in guinea pig brain. In Proceedings of the International Narcotics Research. New Leads in Opioid Research Conference. Edited by van Ree JM, Mulder AH, Wiegant VM, Van Wimersma-Greidanus TB. Amsterdam: Excerpta Medica-Elsevier; 1990:263-264.
7. Samovilova NN, Nagornaya LV, Vinogradov VA: (+)-[3H]SK&F 10,047 binding sites in rat liver. Eur J Pharmacol 1988, 147:259-264.
8. Wolfe SA Jr, Culp SG, de Souza EB: Sigma-receptors in endocrine organs: identification, characterization, and autoradiographic localization in rat pituitary, adrenal, testis, and ovary. Endocrinology 1989, 124:1160-1172.
9. Dumont M, Lemaire S: Interaction of 1,3-di(2-[5-3H]tolyl)guanidine with σ2 binding sites in rat heart membrane preparations. Eur J Pharmacol 1991, 209:245-248.
10. Hellewell SB, Bruce A, Feinstein G, Orringer J, Williams W, Bowen WD: Rat liver and kidney contain high densities of sigma 1 and sigma 2 receptors: characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol 1994, 268:9-18.
11. Kekuda R, Prasad PD, Fei YJ, Leibach FH, Ganapathy V: Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1). Biochem Biophys Res Commun 1996, 229:553-558.
12. Hanner M, Moebius FF, Flandorfer A, Knaus HG, Striessnig J, Kempner E, Glossmann H: Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc Natl Acad Sci 1996, 93:8072-8077.
13. Seth P, Fei YJ, Li HW, Huang W, Leibach FH, Ganapathy V: Cloning and functional characterization of a sigma receptor from rat brain. J Neurochem 1998, 70:922-931.
14. Pan YX, Mei J, Xu J, Wan BL, Zuckerman A, Pasternak GW: Cloning and characterization of a mouse sigma1 receptor. J Neurochem 1998, 70:2279-2285.
15. Mei J, Pasternak GW: Molecular cloning and pharmacological characterization of the rat sigma1 receptor. Biochem Pharmacol 2001, 62:349-355.
16. Hayashi T, Su TP: Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 2007, 131:596-610.
17. Tsai SY, Hayashi T, Mori T, Su TP: Sigma-1 receptor chaperones and diseases. Cent Nerv Syst Agents Med Chem 2009, 9:184-189.
18. Xu J, Zeng C, Chu W, Pan F, Rothfuss JM, Zhang F, Tu Z, Zhou D, Zeng D, Vangveravong S, Johnston F, Spitzer D, Chang KC, Hotchkiss RS, Hawkins WG, Wheeler KT, Mach RH: Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat Commun 2011, 2:380.
19. Ahmed IS, Chamberlain C, Craven RJ: S2R(Pgrmc1): the cytochrome-related sigma-2 receptor that regulates lipid and drug metabolism and hormone signaling. Expert Opin Drug Metab Toxicol 2012, 8:361-370.
20. Su TP, London ED, Jaffe JH: Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems. Science 1988, 240:219-221.
21. Su TP: Sigma receptors. Putative links between nervous, endocrine and immune systems. Eur J Biochem 1991, 200:633-642.
22. McCann DJ, Su TP: Haloperidol-sensitive (+)[3H]SKF-10,047 binding sites (sigma sites) exhibit a unique distribution in rat brain subcellular fractions. Eur J Pharmacol 1990, 188:211-218.
23. Klein M, Canoll PD, Musacchio JM: SKF 525-A and cytochrome P-450 ligands inhibit with high affinity the binding of [3H]dextromethorphan and sigma ligands to guinea pig brain. Life Sci 1991, 48:543-550.
24. Knight AR, Noble A, Wong EHF, Middlemiss DN: The subcellular distribution and pharmacology of the sigma recognition site in the guinea-pig brain and liver. Mol Neuropharmacol 1991, 1:71-75.
25. Ross SB: Heterogeneous binding of sigma radioligands in the rat brain and liver: possible relationship to subforms of cytochrome P-450. Pharmacol Toxicol 1991, 68:293-301.
26. Huang Y-S, Lu H-L, Zhang L-J, Wu Z: Sigma-2 receptor ligands and their perspectives in cancer diagnosis and therapy. Med Res Rev 2013, 00:1-35.
27. Vilner BJ, John CS, Bowen WD: Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res 1995, 55:408-413.
28. John CS, Bowen WD, Varma VM, McAfee JG, Moody TW: Sigma receptors are expressed in human non-small cell lung carcinoma. Life Sci 1995, 56:2385-2392.
29. Wang B, Rouzier R, Albarracin CT, Sahin A, Wagner P, Yang Y, Smith TL, Meric-Bernstam F, Marcelo Aldaz C, Hortobagyi GN, Pusztai L: Expression of sigma 1 receptor in human breast cancer. Breast Cancer Res Treat 2004, 87:205-214.
30. Aydar E, Onganer P, Perrett R, Djamgoz MB, Palmer CP: The expression and functional characterization of sigma (sigma) 1 receptors in breast cancer cell lines. Cancer Lett 2006, 242:245-257.
31. Kashiwagi H, McDunn J, Simon P, Goedegebuure P, Xu J, Jones L, Chang K, Johnston F, Trinkaus K, Hotchkiss R, Mach R, Hawkins W: Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy. Mol Cancer 2007, 6:48.
32. Mach RH, Smith CR, al-Nabulsi I, Whirrett BR, Childers SR, Wheeler KT: Sigma 2 receptors as potential biomarkers of proliferation in breast cancer. Cancer Res 1997, 57:156-161.
33. Bem WT, Thomas GE, Mamone JY, Homan SM, Levy BK, Johnson FE, Coscia CJ: Overexpression of sigma receptors in nonneural human tumors. Cancer Res 1991, 51:6558-6562.
34. Vilner BJ, Bowen WB: Mechanism for neuromodulation and protection? In Mechanism for Neuromodulation and Protection. Ann Arbor: NPP Books; 1992:341-353.
35. Al-Nabulsi I, Mach RH, Wang LM, Wallen CA, Keng PC, Sten K, Childers SR, Wheeler KT: Effect of ploidy, recruitment, environmental factors, and tamoxifen treatment on the expression of sigma-2 receptors in proliferating and quiescent tumour cells. Br J Cancer 1999, 81:925-933.
36. Wheeler KT, Wang LM, Wallen CA, Childers SR, Cline JM, Keng PC, Mach RH: Sigma-2 receptors as a biomarker of proliferation in solid tumours. Br J Cancer 2000, 82:1223-1232.
37. Difilippantonio S, Chen Y, Pietas A, Schluns K, Pacyna-Gengelbach M, Deutschmann N, Padilla-Nash HM, Ried T, Petersen I: Gene expression profiles in human non-small and small-cell lung cancers. Eur J Cancer 2003, 39:1936-1947.
38. Crudden G, Loesel R, Craven RJ: Overexpression of the cytochrome p450 activator hpr6 (heme-1 domain protein/human progesterone receptor) in tumors. Tumour Biol 2005, 26:142-146.
39. van Waarde A, Rybczynska AA, Ramakrishnan N, Ishiwata K, Elsinga PH, Dierckx RA: Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands. Curr Pharm Des 2010, 16:3519-3537.
40. Hou C, Tu Z, Mach R, Kung HF, Kung MP: Characterization of a novel iodinated sigma-2 receptor ligand as a cell proliferation marker. Nucl Med Biol 2006, 33:203-209.
41. Rowland DJ, Tu Z, Xu J, Ponde D, Mach RH, Welch MJ: Synthesis and in vivo evaluation of 2 high-affinity 76Br-labeled sigma2-receptor ligands. J Nucl Med 2006, 47:1041-1048.
42. Tu Z, Dence CS, Ponde DE, Jones L, Wheeler KT, Welch MJ, Mach RH: Carbon-11 labeled sigma2 receptor ligands for imaging breast cancer. Nucl Med Biol 2005, 32:423-430.
43. Tu Z, Xu J, Jones LA, Li S, Dumstorff C, Vangveravong S, Chen DL, Wheeler KT, Welch MJ, Mach RH: Fluorine-18-labeled benzamide analogues for imaging the sigma2 receptor status of solid tumors with positron emission tomography. J Med Chem 2007, 50:3194-3204.
44. Tu Z, Xu J, Jones LA, Li S, Zeng D, Kung MP, Kung HF, Mach RH: Radiosynthesis and biological evaluation of a promising sigma(2)-receptor ligand radiolabeled with fluorine-18 or iodine-125 as a PET/SPECT probe for imaging breast cancer. Appl Radiat Isot 2010, 68:2268-2273.
45. Chu W, Xu J, Zhou D, Zhang F, Jones LA, Wheeler KT, Mach RH: New N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl phenylcarbamate analogs as sigma2 receptor ligands: synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents. Bioorg Med Chem 2009, 17:1222-1231.
46. Waterhouse RN: Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol 2003, 5:376-389.
47. Hajipour AR, Guo LW, Pal A, Mavlyutov T, Ruoho AE: Electron-donating para-methoxy converts a benzamide-isoquinoline derivative into a highly Sigma-2 receptor selective ligand. Bioorg Med Chem 2011, 19:7435-7440.
48. DeHaven-Hudkins DL, Fleissner LC, Ford-Rice FY: Characterization of the binding of [3H](+)-pentazocine to sigma recognition sites in guinea pig brain. Eur J Pharmacol 1992, 227:371-378.
49. DeHaven-Hudkins DL, Ford-Rice FY, Allen JT, Hudkins RL: Allosteric modulation of ligand binding to [3H](+)pentazocine-defined sigma recognition sites by phenytoin. Life Sci 1993, 53:41-48.
50. Nguyen VH, Kassiou M, Johnston GA, Christie MJ: Comparison of binding parameters of sigma 1 and sigma 2 binding sites in rat and guinea pig brain membranes: novel subtype-selective trishomocubanes. Eur J Pharmacol 1996, 311:233-240.
51. Cheng Y, Prusoff WH: Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 1973, 22:3099-3108.
52. Hilton J, Yokoi F, Dannals RF, Ravert HT, Szabo Z, Wong DF: Column-switching HPLC for the analysis of plasma in PET imaging studies. Nucl Med Biol 2000, 27:627-630.
53. Visser EP, Disselhorst JA, Brom M, Laverman P, Gotthardt M, Oyen WJ, Boerman OC: Spatial resolution and sensitivity of the Inveon small-animal PET scanner. J Nucl Med 2009, 50:139-147.
54. Kawamura K, Ishiwata K, Tajima H, Ishii S, Matsuno K, Homma Y, Senda M: In vivo evaluation of [(11)C]SA4503 as a PET ligand for mapping CNS sigma (1) receptors. Nucl Med Biol 2000, 27:255-261.
55. van Waarde A, Buursma AR, Hospers GA, Kawamura K, Kobayashi T, Ishii K, Oda K, Ishiwata K, Vaalburg W, Elsinga PH: Tumor imaging with 2 sigma-receptor ligands, 18 F-FE-SA5845 and 11C-SA4503: a feasibility study. J Nucl Med 2004, 45:1939-1945.
56. Mach UR, Hackling AE, Perachon S, Ferry S, Wermuth CG, Schwartz JC, Sokoloff P, Stark H: Development of novel 1,2,3,4-tetrahydroisoquinoline derivatives and closely related compounds as potent and selective dopamine D3 receptor ligands. Chembiochem 2004, 5:508-518.
57. Mach RH, Huang Y, Freeman RA, Wu L, Vangveravong S, Luedtke RR: Conformationally-flexible benzamide analogues as dopamine D3 and sigma 2 receptor ligands. Bioorg Med Chem Lett 2004, 14:195-202.
58. Cheng YF, Paalzow LK: Linear pharmacokinetics of haloperidol in the rat. Biopharm Drug Dispos 1992, 13:69-76.
59. Verdurand M, Nguyen V, Stark D, Zahra D, Gregoire M-C, Greguric I, Zavitsanou K: Comparison of cannabinoid CB1 receptor binding in adolescent and adult rats: a positron emission tomography study using [18 F]MK-9470. Int J Mol Imaging 2011, 2011:548123.
60. Stachnik J: Inhaled anesthetic agents. Am J Health Syst Pharm 2006, 63:623-634.